
THE POWER OF
**PERSONALIZED
REGENERATION**
WITH HUMAN SMART
EXOSOMES

1 SESSION

UP TO
70 BILLION*

SMART EXOSOMES

Scientifically
Proven Efficacy



*Depending on the protocol applied and patient variables

WHERE PRECISION MEETS INNOVATION

The constant innovation and evolution of our company brings **EVO**, the 4th generation of our Patented Rigenera® technology a new medical device engineered to improve the micrograft solution with greater **precision**.

This exceptional extraction increases the **quantity** of biological cellular components in the AMT® solution up to 50%*, for **faster** and **more effective regeneration**.




Experience the power of

70 BILLION Human Smart Exosomes*

ingrafted in a single session.

*Depending on the protocol applied and patient variables.

SMART MICROBLADE TECHNOLOGY



NEW MEDICAL METAL ALLOY COMPONENTS



DECODING OUR AMT[®] TRIAD


In a groundbreaking revelation from our recent studies, we have successfully quantified the precise number of **Smart Exosomes** within our **AMT[®] Triad** (Autologous Micrografting Technology). This breakthrough finding not only exposes the **autologous** nature of our **exosomes** but also highlights their **tissue-specific** origin and function during the healing process in the human body - *a unique solution for personalized regeneration.*

AMT[®] TRIAD

PROGENITOR CELLS
in 80 um micrografts

HUMAN SMART
EXOSOMES

EXTRA CELULAR MATRIX
with tissue specific growth factors



THE ESSENCE OF SMART EXOSOMES

Meet our Human Smart Exosomes – revolutionary **healing messengers** that make **personalized regenerative** treatment a reality. Unlike any other in the market, these exosomes are the **only** ones **capable** of delivering **precision healing** tailored to each individual's unique needs, thanks to their inherent intelligence derived from their **origin** and **tissue specificity**, enabling them to send the right regenerative message.

Up to 70 BILLION* Human Smart Exosomes in One Session

The First Autologous and Tissue Specific in the market

Personalized Agents to modulate inflammation and healing

No Manipulation for Maximum Safety and No Side Effects

Scientifically Proven Efficacy

*Depending on the protocol applied and patient variables

Studies made by University of Ferrara and University of Barcelona.

AMT[®] TRIAD IN ACTION: HAIR FOLLICLE REGENERATION

Through a **minimally invasive** and **safety** AMT[®] procedure, our **AMT[®] Triad** is injected into the scalp, acting directly within the hair follicle and triggering a **paracrine** action that **reverses** hair **miniaturization** and promotes healthy **hair growth**.

This treatment, backed by several scientific studies^{3,4} and endorsed by renowned doctors worldwide, yields remarkable results:

REMARKABLE
90%
PATIENT
SATISFACTION

↑ Increase
Hair Thickness

↑ Increase
Hair Density


↑ Increase
Cumulative
Hair Thickness

REVERSAL OF HAIR MINIATURIZATION AND PROMOTING HEALTHY HAIR GROWTH

Essential **communication** between **dermal papilla** and **bulge cells** during hair growth is disrupted in Androgenetic Alopecia (AGA). Dihydrotestosterone inhibits Wnt-B-catenin signaling in dermal papilla cells, leading to **shortened anagen** phases and hair miniaturization.

Through exosomes and growth factors, they communicate and reverse the miniaturization process, promoting a natural and harmonious hair follicle cycle⁵.

Restored paracrine communication:
Maintain hair follicle stem cells
proliferation and differentiation.



3. Ruiz RG, Rosell JMC, Ceccarelli G, et al. Progenitor-cell-enriched micrografts as a novel option for the management of androgenetic alopecia. *J Cell Physiol.* 2020;235(5):4587-4593. doi:10.1002/jcp.29335

4. Hu S, Li Z, Lutz H, et al. Dermal exosomes containing miR-218-5p promote hair regeneration by regulating β -catenin signaling. *Sci Adv.* 2020;6(30):eaba1685. Published 2020 Jul 24. doi:10.1126/sciadv.aba1685

5. Gupta AK, Wang T, Rapaport JA. Systematic review of exosome treatment in hair restoration: Preliminary evidence, safety, and future directions. *J Cosmet Dermatol.* 2023;22(9):2424-2433. doi:10.1111/jocd.15869



REMEDII



Worldwide Distributor
of Regenera® technology

Legal headquarters & office

C/ Sant Ferran 10-12, local
08031 Barcelona, Spain

Contact information

+34 93 514 57 56
info@regeneraactiva.com
www.regeneraactiva.com
@regeneraactiva_amt



Worldwide Manufacturer

C.so Galileo Ferraris, 63
10128 Torino, Italy

Via Sestriere 17, 10060
Candiolo (TO), Italy



SCAN TO FIND
OUT MORE



US FDA Establishment
Registration Number: 3010882686

